History
- Jan 2016
- Jan 2016 EdiGene Corporation founded
- Apr 2016
- Established fully owned US subsidiary, EdiGENE Inc. (Now Modalis Therapeutics Inc.)
- Apr 2017
- Initial research collaboration formed with Astellas Pharma Inc.
- Sep 2017
- Obtained license on engineered Cas9 technology from University of Tokyo
- Feb 2019
- Established a license agreement on a genetic disorder with Astellas Pharma Inc.
- Mar 2019
- US subsidiary relocated to the new facility
- Aug 2019
- EdiGene renamed to Modalis Therapeutics
- Sep 2019
- Established 2nd license agreement for additional genetic disorder with Astellas Pharma Inc.
- Nov 2019
- Collaboration agreement with Eisai Co., Ltd.
- Apr 2020
- Modalis Obtains Access to Foundational CRISPR IP
- Aug 2020
- Listing on Mothers, Tokyo Stock Exchange (Ticker symbol: 4883)
- Oct 2021
- US subsidiary relocated to the new facility